Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 May;36(3):177–184. doi: 10.1007/BF01741089

The role of monoclonal antibody A7 as a drug modifier in cancer therapy

K Kitamura 1,✉, T Miyagaki 1, N Yamaoka 1, H Tsurumi 1, A Noguchi 1, T Yamaguchi 1, T Takahashi 1
PMCID: PMC11038366  PMID: 8439978

Abstract

An anticancer antibiotic, neocarzinostatin (NCS), was covalently conjugated to the murine monoclonal antibody A7 (mAb A7), which recognizes the glycoprotein on the cell surface of human colon cancer. The biological and pharmacological properties of the conjugate (A7-NCS) were examined and compared with those of unconjugated NCS. A7-NCS exhibited a strong binding and cytotoxicity to the cell and an antigen-specific tumor accumulation. Significant tumoricidal effects in vivo were observed in the antigen-positive tumor-bearing mice treated with A7-NCS, whereas NCS mixed with mAb A7 and NCS alone were relatively ineffective. In the antigennegative tumor, the tumoricidal effect of A7-NCS was lower than in the antigen-positive tumor. The NCS concentration in blood and tumor were significantly elevated by conjugation to mAb A7. The NCS localization in tumor was higher in the antigen-positive tumor than in the antigen-negative tumor. Death due to acute toxicity was observed at a dose of 20 units (U) NCS in mice treated with unconjugated NCS, whereas toxicity was seen with a much higher dose of NCS (100 U) if the drug was conjugated to the mAb. These findings show that mAb A7 confers more favorable pharmacological properties on an anticancer drug, making it potentially more useful for cancer chemotherapy.

Key words: Monoclonal antibody, Drug modifier, Cancer chemotherapy

Footnotes

This work has been supported in part by a grant-in-aid for cancer research from the Ministry of Education and for the comprehensive 10-year strategy for cancer control from the Ministry of Health and Welfare, Japan

References

  • 1.Arnon R, Sela M. In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumor antibodies. Immunol Rev. 1982;62:5–27. doi: 10.1111/j.1600-065x.1982.tb00387.x. [DOI] [PubMed] [Google Scholar]
  • 2.Atsumi R, Endo K, Kakutani T, Takakura Y, Hashida M, Sezaki H. Disposition characteristics of mytomycin C-dextran conjugate in normal and tumor bearing muscles of rabbits. Cancer Res. 1987;47:5546–5551. [PubMed] [Google Scholar]
  • 3.Davis SS, Illum L. Colloidal delivery systems-opportunities and challengers. In: Tomlinson E, Davis SS, editors. Site-specific drug delivery: cell biology. Medical and pharmaceutical aspects. Chichester: Wiley; 1986. pp. 93–110. [Google Scholar]
  • 4.Dillman RO, Johnson DE, Shawler DL, Koziol JA. Supeority of an acid-labile daunomycin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res. 1988;48:6097–6102. [PubMed] [Google Scholar]
  • 5.Ebina T, Ohtsuki K, Seto M, Ishida N. Specific G2 block in Hela-S3 cells by neocarzinostatin. Eur J Cancer. 1975;11:155–158. doi: 10.1016/0014-2964(75)90110-3. [DOI] [PubMed] [Google Scholar]
  • 6.Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2 and Fab in tumors. Cancer Res. 1989;49:5656–5663. [PubMed] [Google Scholar]
  • 7.Fujita H, Nakayama N, Sawabe T, Kimura K. In vivo distribution of and inactivation of neocarzinostatin (in Japanese) Jpn J Antibiot. 1970;23:471–478. [PubMed] [Google Scholar]
  • 8.Fukuda K. The study of targeting chemotherapy against the gastrointestinal cancer (the preparation of anticancer drug-monoclonal antibody conjugate and the investigation about its biological activity (in Japanese) Akita J Med. 1985;12:451–468. [Google Scholar]
  • 9.Gallego J, Price MR, Baldwin RW. Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumor activity. Int J Cancer. 1984;33:737–744. doi: 10.1002/ijc.2910330605. [DOI] [PubMed] [Google Scholar]
  • 10.Garnett MC, Embleton MJ, Jacob E, Baldwin RW. Preparation and properties of a drug-carrier-antibody conjugates showing selective antibody-directed cytotoxicity in vitro. Int J Cancer. 1983;31:661–670. doi: 10.1002/ijc.2910310520. [DOI] [PubMed] [Google Scholar]
  • 11.Greenwood FC, Hunter WM, Glover JS. The preparation of 131-I labeled human growth hormone of high specific radioactivity. Biochem J. 1963;89:114–123. doi: 10.1042/bj0890114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gregoriads G, Senior J, Wolff B, Kirby C. Fate of liposomes in vivo control leading to targeting. In: Gregoriadis G, Poste G, Senior J, Trouet A, editors. Receptor-mediated targeting of drugs. New York: Plenum; 1984. pp. 243–266. [Google Scholar]
  • 13.Hagiwara A, Takahashi T, Lee R, Ueda T, Takeda M, Itoh T. Chemotherapy for carcinoma peritonitis and pleuritis with MMCCH, mitomycin C adsorbed on activated carbon particles. Cancer. 1987;59:245–251. doi: 10.1002/1097-0142(19870115)59:2<245::aid-cncr2820590212>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  • 14.Hirano T, Ohashi S, Morimoto S, Tsukada K, Kobayashi T, Tsukagoshi S. Synthesis of antitumor-active conjugates of Adriamycin or daunomycin with the copolymer of divinyl ether and maleic anhydride. Makromol Chem. 1986;187:2815–2824. [Google Scholar]
  • 15.Hoes CJT, Potman W, von Heeswijk WA, Mud RJ, de Mooth BG, Greve J, Feijen J. Optimization of macromolecular prodrugs of the antitumor antibiotics Adriamycin. J Controlled Release. 1985;2:205–213. [Google Scholar]
  • 16.Ishida N, Miyazaki K, Kumagai K, Rikimaru M. Neocarzinostatin, an antitumor antibiotic of high molecular weight. J Antibiot (Tokyo) 1965;18:68–71. [PubMed] [Google Scholar]
  • 17.Kanellos J, Pietersz GA, Mckenzie IFC. Studies of methotrexate-monoclonal antibody conjugate or immunotherapy. JNCI. 1985;75:319–332. [PubMed] [Google Scholar]
  • 18.Kinami Y, Miyazaki H, Koyama F, Noguchi M, Konishi T, Furukawa S, Nishida Y, Miyazaki I. The treatment of pancreatic carcinoma with neocarzinostatin (in Japanese) J Jpn Soc Cancer Ther. 1975;10:502–508. [PubMed] [Google Scholar]
  • 19.Kitamura K, Takahashi T, Yamaguchi T, Yokota T, Noguchi A, Amagai T, Imanishi J. Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer. Tohoku J Exp Med. 1989;157:83–93. doi: 10.1620/tjem.157.83. [DOI] [PubMed] [Google Scholar]
  • 20.Kitamura K, Takahashi T, Tsurumi H, Takashina K, Noguchi A, Noguchi AK, Okuzumi J, Yamaguchi T. Pharmacokinetical analysis of the monoclonal antibody A7-neocarzinostatin conjugate adminstered to nude mice. Tohoku J Exp Med. 1991;164:203–211. doi: 10.1620/tjem.164.203. [DOI] [PubMed] [Google Scholar]
  • 21.Kitazima K. The clinical evaluation of a new antileukemic agent. Neocarzinostation (in Japanese) Acta Haematol Jpn. 1974;37:767–772. [PubMed] [Google Scholar]
  • 22.Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  • 23.Kotanagi H, Takahashi T, Masuko T, Hashimoto Y, Koyama K. A monoclonal antibody against human colon cancers. Tohoku J Exp Med. 1986;148:353–360. doi: 10.1620/tjem.148.353. [DOI] [PubMed] [Google Scholar]
  • 24.Lazarus H, Raso V, Samy TSA. In vitro inhibition of human leukemic cells (CCRF-CEM) by agarose-immobilized neocarzinostatin. Cancer Res. 1977;37:3731–3736. [PubMed] [Google Scholar]
  • 25.Mukojima T, Kimura K. Immunological assay of neocarzinostatin (in Japanese) Jpn J Cancer Clin. 1974;20:245–248. [Google Scholar]
  • 26.Napier MA, Holmquist B, Strydam DJ, Goldenberg IH. Neocarzinostatin: spectral characterization and separation of non-protein chromophore. Biochem. Biophys Res Commun. 1979;89:635–642. doi: 10.1016/0006-291x(79)90677-6. [DOI] [PubMed] [Google Scholar]
  • 27.Okamoto Y, Konno A, Togawa K, Kato T, Tamakawa Y, Amano Y. Arterial chemoembolization with cisplatin microcapsules. Br J Cancer. 1986;53:369–375. doi: 10.1038/bjc.1986.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Pietersz GA, Smyth MJ, Mckenzie IFC. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. Cancer Res. 1988;48:926–931. [PubMed] [Google Scholar]
  • 29.Pimm MV, Jones JA, Price MR, Middle JG, Embleton MJ, Baldwin RW. Tumor localization of monoclonal antibody against a rat mammary carcinoma and suppresion of tumor growth with Adriamycin-antibody conjugate. Cancer. 1982;12:125–134. [Google Scholar]
  • 30.Pratesi G, Savi G, Pezzoni G, Bellini O, Penco S, Tinelli S, Zunino F. Poly-l-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug. Br J Cancer. 1985;52:841–848. doi: 10.1038/bjc.1985.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Sands H, Jones PL, Shah SA, Palme D, Vessela RL, Gallagher BM. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res. 1988;48:188–193. [PubMed] [Google Scholar]
  • 32.Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, Yarmush ML. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effect of antibody immunological properties and tumor antigen expression levels. Cancer Res. 1992;52:357–366. [PubMed] [Google Scholar]
  • 33.Swabb EA, Wei J, Gullino PM. Diffusion and convection in normal and neoplastic tissues. Cancer Res. 1984;34:2814–2822. [PubMed] [Google Scholar]
  • 34.Takahashi M, Toriyama K, Maeda H, Kikuchi M, Kumagai K, Ishida N. Clinical trials of a new antitumor polypeptide: neocarzinostatin (NCS) Tohoku J Exp Med. 1969;98:273–280. doi: 10.1620/tjem.98.273. [DOI] [PubMed] [Google Scholar]
  • 35.Takahashi T, Ueda S, Kono K, Majima S. Attempt at local administration of anticancer agents in the form of fat emulsion. Cancer. 1976;38:1507–1514. doi: 10.1002/1097-0142(197610)38:4<1507::aid-cncr2820380411>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 36.Tsukada Y, Kato Y, Umemeto N, Takeda Y, Hara T, Hirai H. An anti-alpha-fetoprotein antibody-daunomycin conjugate with a novel poly-l-glutamic acid derivative as intermediate carrier. JNCI. 1984;13:721–729. [PubMed] [Google Scholar]
  • 37.Yamada N, Ishii K, Zeze F, Nakayama K. Excretion of anticancer and antimicrobial drugs into pancreatic juice (in Japanese) Jpn J Gastroenterol. 1973;71:901–906. [PubMed] [Google Scholar]
  • 38.Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, Inoue S. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug Adriamycin-conjugated poly(ethyleneglycol)-poly(aspartic acid) block copolymer. Cancer Res. 1990;50:1693–1700. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES